Tirzepatide vs Retatrutide: A Phase 3 Trial Chemical Against an Approved Label

Retatrutide and tirzepatide are often sold side by side by the same grey-market vendors, as if they were two flavours of the same product. They are at very different stages. Tirzepatide has an FDA-approved label. Retatrutide has trials in progress, a few published results and a press release.

At a glance

Full pages: Retatrutide · Tirzepatide

Legal status, side by side

Retatrutide

Tirzepatide

Mechanism

Tirzepatide is a single synthetic peptide that binds and activates two receptors, GIP and GLP-1. Its label states that it enhances first- and second-phase insulin secretion and reduces glucagon, both in a glucose-dependent manner.

Retatrutide is engineered to activate those same two receptors plus the glucagon receptor. Eli Lilly, the trial sponsor, says the added glucagon activity is intended to raise energy expenditure and hepatic fat metabolism. That comes on top of the appetite and insulin effects of the other two receptors. It is the sponsor’s design rationale, a real pharmacological hypothesis, but no approved human product exists to show it.

What the evidence shows

Tirzepatide’s approval rests on FDA review of placebo-controlled randomised trials, across four indications spanning Mounjaro and Zepbound. The adverse-reaction rates on its label come from that same reviewed trial data.

Retatrutide’s biggest completed study is TRIUMPH-1, a Phase 3, randomised, double-blind, placebo-controlled trial of 2,335 people. Its primary outcome was body weight change at 80 weeks. It is registered on ClinicalTrials.gov as completed, but as of this writing no results have been posted there and no peer-reviewed publication exists. What exists is a company press release. Eli Lilly reported, as topline figures, mean weight loss at week 80 of:

• 19.0% at 4 mg
• 25.9% at 9 mg
• 28.3% at 12 mg
• 2.2% on placebo

The same release gave discontinuation due to adverse events as 4.1% at 4 mg, 6.9% at 9 mg and 11.3% at 12 mg, against 4.9% on placebo. Neither FDA nor a journal’s peer reviewers has independently reviewed any of these figures.

Two smaller retatrutide trials have been published:

• A 48-week Phase 2 obesity trial of 338 adults (New England Journal of Medicine, 2023) reported mean weight change of -24.2% on 12 mg against -2.1% on placebo.
• TRANSCEND-T2D-1 was a 40-week Phase 3 trial of 537 adults with type 2 diabetes (The Lancet, 2026). It reported weight loss of 11.5% to 15.3% across the 4, 9 and 12 mg doses, against 2.6% on placebo.

Both are peer-reviewed and both were funded by the developer. Neither is an FDA review. Lilly is also running TRIUMPH-Outcomes, a roughly 10,000-person cardiovascular and kidney outcomes trial that is still active.

Retatrutide

Tirzepatide

Safety data: a label versus a press release

Tirzepatide carries a boxed warning: it causes thyroid C-cell tumours in rats, human relevance unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. At the 15 mg maintenance dose in the Zepbound trial data, the rates were nausea 28%, diarrhoea 23%, vomiting 13% and constipation 11%. These rates sit on an FDA-reviewed label.

Retatrutide has no FDA-reviewed safety label, no confirmed adverse-reaction rate and no defined dose. Its human safety data come from the company press release above and from the published trials:

• Phase 2 obesity trial: gastrointestinal events were the most common, rose with dose and were mostly mild to moderate. Heart rate rose with dose, peaking at 24 weeks.
• TRANSCEND-T2D-1: 2% to 5% of people on retatrutide stopped because of adverse events, against none on placebo.

Retatrutide also activates a third receptor, glucagon, that tirzepatide does not touch. Whether that adds any distinct long-term risk in humans has not been established, because FDA has not reviewed retatrutide.

The grey market: a shared problem, with one extra step

FDA has documented dosing errors, counterfeit product and fraudulent labelling across the compounded and “research use only” GLP-1 supply generally, tirzepatide included. Retatrutide carries all of that risk plus one more fact. FDA has stated that it is not eligible for compounding under federal law at all. It is not a component of an FDA-approved drug and has not been found safe and effective for any condition. FDA has warned telehealth companies, active pharmaceutical ingredient distributors and outsourcing facilities specifically over unapproved retatrutide.

Cost and access

Tirzepatide is dispensed at retail and mail-order pharmacies as the FDA-approved products Mounjaro and Zepbound, on a prescription for one of their approved indications. What a patient pays depends on the indication being treated, the prescriber’s diagnosis and the insurance plan. This page gives no dollar figure, because it would be stale within weeks.

Retatrutide has no legitimate purchase pathway at any price. It is not an approved product, and FDA has stated it cannot legally be compounded. Any price attached to “retatrutide” online is for an unapproved research chemical sold outside the drug-approval system. It is not a medicine, and this page does not treat it as a cost of treatment.

Related

• Retatrutide (LY3437943)
• Tirzepatide (Mounjaro, Zepbound)
• Semaglutide vs tirzepatide
• Best GLP-1 for weight loss: the approved options compared
• Are peptides safe?

Common questions

Is retatrutide better than tirzepatide for weight loss?

This page does not declare a winner. Tirzepatide has FDA-reviewed trial data behind an approved label. Retatrutide's largest obesity trial has released only topline, company-reported figures, not yet published or reviewed by FDA. Its published results come from a smaller Phase 2 trial and a Phase 3 diabetes trial. Setting an approved label against an unreviewed press release is not a like-for-like comparison, whatever the raw percentages suggest.

Is retatrutide FDA-approved like tirzepatide?

No. Tirzepatide is FDA-approved as Mounjaro and Zepbound, each with its own indication and label. Retatrutide has no FDA-approved product and no approved indication. FDA has stated it cannot legally be compounded, because it is not a component of an approved drug and has not been found safe and effective for any condition.

What is the mechanism difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide is engineered to activate those two plus a third, the glucagon receptor. The trial sponsor says the added glucagon activity is intended to raise energy expenditure and hepatic fat metabolism. That is the sponsor's design rationale, not a fact shown in an approved human product.

Can I legally buy retatrutide the way I can get tirzepatide?

Not through the same channel. Tirzepatide requires a prescription for an FDA-approved product. Retatrutide has no lawful consumer channel. FDA has warned telehealth companies, ingredient distributors and outsourcing facilities specifically over unapproved retatrutide, and it cannot legally be compounded at all.

Does retatrutide burn fat or muscle?

This has not been established, because no FDA-reviewed data exists for retatrutide. The company topline report from TRIUMPH-1 described total body weight change only. It did not split the result into fat mass and lean mass, and no body-composition analysis has been published or reviewed by FDA. Until that data is released, no claim about which tissue is lost can be verified.

What is more powerful than tirzepatide?

No FDA-approved product has been shown, in a reviewed head-to-head trial, to outperform tirzepatide. Retatrutide's company-reported topline figures describe a larger percentage weight loss. But that sets an unreviewed press release against an FDA-reviewed label. Until TRIUMPH-1's data is published or reviewed by FDA, calling it "more powerful" compares a claim to a verdict, not two verdicts.

Does retatrutide work immediately?

No. TRIUMPH-1, retatrutide's own trial, was built around a slow, cumulative outcome: body weight change at 80 weeks was the primary endpoint, not days or weeks. Receptor agonists in this class generally build their effect over months of continued dosing. Nothing in the public topline data describes an early or immediate result after a single injection.

When is the best time to inject retatrutide?

There is no FDA-approved dosing or injection-timing guidance, because no retatrutide product is approved for any use. Timing protocols circulating online come from an undisclosed trial schedule, an unregulated vendor or informal practice, so this page does not repeat them. Tirzepatide's label does specify dosing and timing for its approved indications; retatrutide has no approved equivalent.

What are the risks of taking retatrutide?

In the Phase 2 obesity trial, gastrointestinal side effects were the most common and rose with dose, as did heart rate. In the Phase 3 diabetes trial, 2% to 5% of people on retatrutide stopped because of adverse events. Lilly's unreviewed topline figures for TRIUMPH-1 put that at up to 11.3% on 12 mg. Beyond that, its risks are not fully known: there is no FDA-reviewed safety label, and a grey-market vial carries no verified identity, purity or dose. See [safety data](#safety-data-a-label-versus-a-press-release).

References (6 sources)

Show

Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.

1. 1.Jastreboff AM, Kaplan LM, Frías JP et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.Randomised trialPMID 37366315
2. 2.Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413.Randomised trialPMID 42250575
3. 3.Urva S, Coskun T, Loh MT et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881.Randomised trialPMID 36354040
4. 4.MOUNJARO (tirzepatide) injection - full prescribing information, including boxed warning, dosing schedule and adverse reaction rates.- DailyMed, National Library of Medicinelabel
5. 5.ZEPBOUND (tirzepatide) injection - full prescribing information for the weight management and obstructive sleep apnoea indications.- DailyMed, National Library of Medicinelabel
6. 6.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - states retatrutide cannot legally be compounded, and documents dosing errors, counterfeit product and fraudulent labelling for the wider grey-market GLP-1 supply.- US Food and Drug Administrationregulatory

Keep reading

Related guides

All guides →

• bpc-157 vs tb-500BPC-157 vs TB-500: How the Two DifferTwo different molecules with different literatures, sold as one healing stack. Structure, human data, legal status and WADA bans, side by side.2 min readRead guide→
• cjc-1295 vs sermorelinCJC-1295 vs Sermorelin: One Sequence, Two HistoriesBoth are built on the first 29 amino acids of GHRH. One was approved for children and later withdrawn by its sponsor; the other never got past Phase 2.7 min readRead guide→
• hgh peptidesHGH Peptides vs Recombinant HGH: Two Different Drugs, Compared'HGH peptides' (GH secretagogues) prompt the pituitary to release growth hormone. Recombinant HGH is that hormone itself, FDA-approved for defined deficiencies only.7 min readRead guide→
• ipamorelin vs sermorelinIpamorelin vs Sermorelin: Two Receptors, Two HistoriesBoth release growth hormone from the pituitary, through different receptors. One was approved for children; the other stopped at Phase 2 for lack of efficacy.5 min readRead guide→
• nad+ vs peptidesNAD+ Injections vs Peptides: A Coenzyme Is Not an Amino-Acid ChainNAD+ injections are a coenzyme therapy, not a peptide. Structure, legal status and evidence, compared side by side with the peptides they get sold alongside.4 min readRead guide→
• oral vs injectable bpc-157Oral vs Injectable BPC-157: What Each Route Has Actually Been Tested ForNo published human study has given BPC-157 by mouth or by subcutaneous injection. What the record shows for each route, and what it cannot tell you.6 min readRead guide→